Exelixis announces results from trial evaluating XB002
Study involves patients with advanced common cancers and solid tumours
Read More
Tag: Exelixis
FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population
Read More
NICE rules against first-line use of Ipsen’s Cabometyx
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Read More
Cabometyx trial halted early on success in liver cancer
A late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed.
Read More
Exelixis links with BMS to test potential cancer combo
Exelixis and Bristol-Myers Squibb Company have formed a clinical development collaboration to evaluate a potential new combination therapy for the treatment of various cancers.
Read More
NICE draft guidelines reject Ipsen’s Cabometyx
The National Institute for Health and Care Excellence has issued its first draft guidelines on Ipsen’s Cabometyx, recommending against the drug’s routine use on the National Health Service as a treatment for pre-treated advanced renal cell carcinoma.
Read More
EU nod for Exelixis’ kidney cancer drug
European regulators have approved a new second-line treatment option for patients with advanced kidney cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
